TY  - BOOK
AU  - Balamurugan,K.
AU  - Chandra,K.
AU  - Latha,S.S.
AU  - Swathi,M.
AU  - Joshi,M.B.
AU  - Misra,P.
AU  - Parsa,K.V.
TI  - PHLPPs: Emerging players in metabolic disorders
KW  - PHLPP1
KW  - PHLPP2
KW  - TYPE 2 DIABETES
KW  - CARDIOVASCULAR DYSFUNCTION
KW  - ATHEROSCLEROSIS
N2  - That reversible protein phosphorylation by kinases and phosphatases occurs in metabolic disorders is well known. Various studies have revealed that a multi-faceted and tightly regulated phosphatase, pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP)-1/2 displays robust effects in cardioprotection, ischaemia/reperfusion (I/R), and vascular remodelling. PHLPP1 promotes foamy macrophage development through ChREBP/AMPK-dependent pathways. Adipocyte-specific loss of PHLPP2 reduces adiposity, improves glucose tolerance,and attenuates fatty liver via the PHLPP2-HSL-PPAR? axis. Discoveries of PHLPP1-mediated insulin resistance and pancreatic ? cell death via the PHLPP1/2-Mst1-mTORC1 triangular loop have shed light on its significance in diabetology. PHLPP1 downregulation attenuates diabetic cardiomyopathy (DCM)by restoring PI3K-Akt-mTOR signalling. In this review, we summarise the functional role of, and cellular signalling mediated by, PHLPPs in metabolic tissues and discuss their potential as therapeutic targets
UR  - https://drive.google.com/file/d/1CbE8FcZu8GG-_UdOqtU8A4Z4xs04r-v_/view?usp=drivesdk
ER  -